Reply to Wei Liu, Katherine Zukotynski, and Glenn Bauman's Letter to the Editor re: Rachel M. Glicksman, Ur Metser, Douglass Vines, et al. Curative-intent Metastasis-directed Therapies for Molecularly-defined Oligorecurrent Prostate Cancer: A Prospective Phase II Trial Testing the Oligometastasis Hypothesis. Eur Urol 2021;80:374-82

Affiliations

¹ Department of Radiation Oncology, University of Toronto, Toronto, Canada; Radiation Medicine Program, Princess Margaret Cancer Centre, University Health Network, Toronto, Canada. Electronic address: rachel.glicksman@rmp.uhn.ca.
² Department of Radiation Oncology, University of Toronto, Toronto, Canada; Radiation Medicine Program, Princess Margaret Cancer Centre, University Health Network, Toronto, Canada; TECHNA Institute, University Health Network, Toronto, Canada.

Comment

Rachel M Glicksman et al. Eur Urol. 2021 Sep.

. 2021 Sep;80(3):e79-e80.

doi: 10.1016/j.eururo.2021.06.004. Epub 2021 Jun 20.

¹ Department of Radiation Oncology, University of Toronto, Toronto, Canada; Radiation Medicine Program, Princess Margaret Cancer Centre, University Health Network, Toronto, Canada. Electronic address: rachel.glicksman@rmp.uhn.ca.
² Department of Radiation Oncology, University of Toronto, Toronto, Canada; Radiation Medicine Program, Princess Margaret Cancer Centre, University Health Network, Toronto, Canada; TECHNA Institute, University Health Network, Toronto, Canada.

No abstract available

Comment in

Urological Oncology: Prostate Cancer.
Taneja SS. Taneja SS. J Urol. 2021 Dec;206(6):1519-1522. doi: 10.1097/JU.0000000000002226. Epub 2021 Sep 9. J Urol. 2021. PMID: 34496606 No abstract available.

Curative-intent Metastasis-directed Therapies for Molecularly-defined Oligorecurrent Prostate Cancer: A Prospective Phase II Trial Testing the Oligometastasis Hypothesis.
Glicksman RM, Metser U, Vines D, Valliant J, Liu Z, Chung PW, Bristow RG, Finelli A, Hamilton R, Fleshner NE, Perlis N, Zlotta AR, Green D, Bayley A, Helou J, Raman S, Kulkarni G, Catton C, Lam T, Chan R, Warde P, Gospodarowicz M, Jaffray DA, Berlin A. Glicksman RM, et al. Eur Urol. 2021 Sep;80(3):374-382. doi: 10.1016/j.eururo.2021.02.031. Epub 2021 Mar 6. Eur Urol. 2021. PMID: 33685838 Clinical Trial.
Re: Rachel M. Glicksman, Ur Metser, Douglass Vines, et al. Curative-intent Metastasis-directed Therapies for Molecularly-defined Oligorecurrent Prostate Cancer: A Prospective Phase II Trial Testing the Oligometastasis Hypothesis. Eur Urol 2021;80:374-82.
Liu W, Zukotynski K, Bauman G. Liu W, et al. Eur Urol. 2021 Sep;80(3):e77-e78. doi: 10.1016/j.eururo.2021.06.003. Epub 2021 Jun 12. Eur Urol. 2021. PMID: 34130872 No abstract available.